Generated by AI
Bio-Rad Laboratories Inc. is a life sciences and clinical diagnostics company that develops, manufactures, and markets products used in research laboratories, biopharmaceutical workflows, and healthcare testing. Bio-Rad Laboratories Inc. serves two main business segments: Life Science and Clinical Diagnostics. Its Life Science portfolio includes instruments, reagents, consumables, software, and content used to separate, purify, identify, and analyze biological materials such as cells, proteins, and nucleic acids. Its Clinical Diagnostics offerings include test systems, test kits, informatics tools, and quality controls used in areas such as diabetes monitoring, blood typing, infectious disease testing, autoimmune disorders, and genetic analysis. The company’s products are used by universities, hospitals, public health organizations, commercial laboratories, biotechnology firms, pharmaceutical companies, and food and environmental testing customers. Headquartered in Hercules, California, Bio-Rad Laboratories Inc. is recognized as a global supplier of tools that support scientific discovery and diagnostic decision-making.
Website1000 Alfred Nobel Drive
Hercules, CA, 94547
United States
The latest articles about BIO.
Cut costs and accelerate safety assessments with human-relevant in vitro models, AI, organ-on-chip and high-throughput screening amid regulatory and ethical shifts.Dublin, Nov. 10, 2026 (GLOBE NEWSWIRE) -- "In Vitro Toxicology Testing - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global in vitro toxicology testing market was valued at US$14 billion in 2025 and is projected to reach US$27.4 billion by 2032, expanding at a compound annual growth rate
Elliott Investment Management has taken an activist position in Bio-Rad Laboratories (NYSE:BIO), pushing for changes at the diagnostics group. The investor is calling out what it views as hidden value at Bio-Rad, including the company’s stake in Sartorius. Elliott is also urging a review of operations and capital allocation, which could lead to restructuring or asset monetization moves. The new activist pressure from Elliott on Bio-Rad’s operations and Sartorius stake is important, but it...
Bio-Rad Laboratories reported third quarter 2026 sales of US$656.4 million and net income of US$458.6 million, compared with a loss a year earlier, alongside a US$49.8 million impairment of purchased intangibles. The swing from loss to profit, supported by stronger international revenue surprises in Asia and EMEA, highlights how overseas demand is influencing Bio-Rad Laboratories' current earnings mix. The focus now is on how this sharp earnings turnaround at Bio-Rad Laboratories could...
Summary of Oct 29's posts. Generated by AI.
Summary of Oct 20's posts. Generated by AI.
Summary of May 18's posts. Generated by AI.
Investors talking about BIO also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.